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Introduction
Cardiovascular magnetic resonance (CMR) with delayed
enhancement (DE) can provide in vivo assessment of myo-
cardial fibrosis. DE is an independent predictor of cardio-
vascular morbidity and mortality in ischemic and non-
ischemic dilated cardiomyopathy but its clinical signifi-
cance in hypertrophic cardiomyopathy (HCM) remains
unresolved.
Purpose
To characterize the clinical profile and short-term clinical
outcome of DE in a large cohort of HCM patients.
Methods
Cine and CMR-DE were performed in 202 HCM patients
(42 ± 17 years; 71% male) with a mean follow-up period
of 607 ± 127 days. Adverse cardiovascular events are tab-
ulated as a combined end-point of: sudden death, appro-
priate ICD discharge and progressive heart failure
symptoms.
Results
DE was identified in 103 (51%) HCM patients, occupying
9 ± 11% (range 0.2 to 51%) of LV myocardial volume,
including 12% with DE > 25%. DE was present all 10
patients with ejection fraction (EF) ≤ 50% (i.e., end-stage
phase), 9/10 (90%) with EF 51–59% and 84/182 (45%)
with EF ≥ 60% (p < 0.001). %DE was inversely related to
EF (r = -0.4; p < 0.001), most extensive in patients with EF
≤ 50% (27% vs.9% for other patients, p < 0.001) and an
independent predictor of EF (r = -0.6; p < 0.001). Of the
182 patients with normal EF ≥ 60%, 49 (27%) were both
asymptomatic and had DE (7 ± 7% of LV; 51% transmu-
ral), including 7 patients ≥ 60 years. The cardiovascular
event rate in HCM patients with DE was higher compared
to patients without DE but did not achieve statistical sig-
nificance (2.5% vs. 3.5%; p = 0.3). In addition, %DE was
greater in patients with adverse events (11.7% vs. 9.3%; p
= 0.6) with no association with heart failure symptoms (p
= 0.1) and age (r = 0.05; p = 0.6).
Conclusion
In a large HCM cohort, DE was common and often occu-
pied substantial areas of LV myocardium. DE was an inde-
pendent predictor of systolic dysfunction, but also
occurred frequently in association with preserved LV func-
tion and absence of heart failure symptoms, including
patients of advanced age. Over a short-term follow-up, DE
was associated with greater (but not statistically signifi-
cant) likelihood of adverse cardiovascular events. These
data suggest, at present, prudent restraint is appropriate
before altering HCM management strategies based solely
on presence of DE, but also support further longitudinal
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